View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2020

First US clinical trial of Covid-19 vaccine candidate begins

The first US clinical trial of a Covid-19 vaccine candidate, which is Moderna’s mRNA-1273, has started at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

The first US clinical trial of a Covid-19 vaccine candidate, which is Moderna’s mRNA-1273, has started at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.

Funded by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID), the trial has dosed its first participant.

mRNA-1273 is an mRNA vaccine designed to target SARS-CoV-2 encoding a prefusion stabilised form of the Spike (S) protein. Moderna selected the candidate in alliance with the Vaccine Research Center (VRC) at the NIAID.

The Coalition for Epidemic Preparedness Innovations (CEPI) funding supported the production of the first clinical batch.

During the Phase I trial, the safety and immunogenicity of 25μg, 100μg, 250μg dose levels of mRNA-1273 given on a two-dose vaccination schedule 28 days apart will be assessed in a total of 45 healthy adults aged 18 to 55.

The study involves a follow-up of 12 months after the second vaccination.

The primary objective is the safety and reactogenicity of a two-dose vaccination schedule, while the secondary objective is immunogenicity to the SARS-CoV-2 S protein.

Moderna chief medical officer Tal Zaks said: “This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity. We are actively preparing for a potential Phase II study under our own IND.

“We are grateful to NIH for their ongoing collaboration and to CEPI for funding the initial manufacturing of mRNA-1273 and are proud to be included with the many companies, worldwide health agencies and NGOs working on a possible response to the novel coronavirus outbreak.”

The potential Phase II and any subsequent trials will further evaluate the safety and immunogenicity of the vaccine candidate in a larger population. Moderna has already started manufacturing the mRNA-1273 material for the Phase II study.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology